Two important drug classes used in CKD associated with T2D are sodium-glucose cotransporter-2 inhibitors (SGLT2is) and the nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone. This evidence concerns the gene SLC5A2 and chronic kidney disease.